Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation.

Date publication

mars 2013

Journal

Transplantation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr CHALOPIN Jean-Marc , Pr DUCLOUX Didier , Dr FERRAND Christophe

Tous les auteurs :
Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Simula-Faivre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Borg C, Saas P, Ducloux D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23388733

Résumé

Fractalkine (CX3CL1) and its receptor (CX3CR1) are involved in antitumor immunity. Two common single nucleotide polymorphisms of the CX3CR1 gene, V249I and T280M, have been associated with reduced fractalkine signaling characterized by decreased adhesive function, signaling, and chemotaxis of leukocytes. We hypothesized that a renal transplant recipient (RTR) carrying the homozygous I249M280 genotype could experience more cancer due to lower CX3CL1-dependent antitumorigenic effects.

Mots clés

Adult, Female, Genetic Predisposition to Disease, Humans, Immunity, Innate, Kidney Transplantation, adverse effects, Male, Middle Aged, Neoplasms, genetics, Polymorphism, Single Nucleotide, Proportional Hazards Models, Receptors, Chemokine, genetics

Référence

Transplantation. 2013 Mar;95(5):728-32